Nano Biotechnology Market Overview
Nano Biotechnology Market Size was valued at USD 5.1 Billion in 2022. The Nano Biotechnology market industry is projected to grow from USD 5.58 Billion in 2023 to USD 11.6 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.60% during the forecast period (2023 - 2032). Increased demand for urgent disease treatment an increase in the need for new medical inventions, more money being spent on research and development, are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Nano Biotechnology Market Trends
- Advancements in nanotechnology is driving the market growth
The growth and development of the nanobiotechnology market have been significantly influenced by advances in nanotechnology. The control and manipulation of materials at the nanoscale, which typically ranges from 1 to 100 nanometers, is the subject of nanotechnology. At this scale, materials display distinctive qualities and behaviours that can be exploited for a variety of biotechnological applications. The creation of innovative nanomaterials is one of the main ways that developments in nanotechnology are shaping the market. Nanoparticles may now be precisely engineered, allowing for precise control over their size, shape, surface characteristics, and composition. With this degree of control, it is possible to create nanoparticles that have specific capabilities and can communicate with biological systems on a molecular level. For instance, targeting ligands or antibodies can be added to nanoparticles to make them precisely bind to particular cells or tissues, enabling targeted drug delivery or imaging. Drug delivery methods have undergone a revolution thanks to the capacity to create nanoparticles with desired features. Drugs can be attached to nanoparticle surfaces or encapsulated within their structures for protection and controlled release. This makes it possible to administer treatments in a tailored manner to particular cells or tissues, reducing unwanted side effects and enhancing the effectiveness of the treatment. The blood-brain barrier is one biological barrier that nanoparticles can cross, making it easier to deliver medications to previously inaccessible locations.
Additionally, developments in nanotechnology have produced nanosensors and nanodevices, which have profound effects on monitoring and diagnosis. Nanosensors have great sensitivity and selectivity for detecting and measuring particular biomarkers or chemicals. They provide real-time monitoring of numerous physiological parameters or disease markers by integrating into wearable devices, lab-on-a-chip platforms, or implanted sensors. Through early identification and intervention, this has the potential to revolutionise disease diagnosis. Tissue engineering and regenerative medicine are two more fields where nanotechnology has made substantial progress. Nanoscale scaffolds and matrices that resemble the natural extracellular matrix (ECM) of tissues have been created by researchers. These scaffolds can aid in tissue regeneration, encourage cell adhesion, proliferation, and differentiation, and give cells structural support. Additionally, bioactive compounds, growth factors, or stem cells can be delivered via nanomaterials to aid in tissue regeneration and repair.
Additionally, interdisciplinary research and cooperation have been sparked by the integration of nanotechnology with other disciplines like biology, chemistry, and engineering. This convergence of knowledge has led to ground-breaking breakthroughs in nanobiotechnology and creative solutions. The development and translation of nanotechnology-based technologies into useful applications have been hastened through cooperative efforts between academic institutions, research organisations, and industry participants. Additionally, nanotechnology developments are in line with the rising desire for personalised medicine. The goal of personalised medicine is to modify a patient's medical care according to their unique genetic, molecular, and clinical characteristics. Molecular level focused and precise interventions are made possible by nanotechnology, allowing for personalised medicine administration, diagnostics, and monitoring. In order to interact with certain cells, tissues, or molecules, nanoscale instruments and devices can be created, making treatments more precise and tailored.
Advancements in nanotechnology have also been significantly fueled by government funding and support. The potential of nanotechnology and its applications in a variety of fields, including biotechnology, are acknowledged by governments all over the world. Through funding initiatives, grants, and research programmes they assist the field's research and development activities. This assistance encourages teamwork among government, business, and academic institutions by improving information sharing, resource access, and collaborative research projects. In conclusion, the market for nanobiotechnology has been significantly impacted by advances in nanotechnology. The area of biotechnology has undergone a revolution due to the development of innovative drug delivery systems, tissue engineering scaffolds, enhanced imaging tools, and the capacity to manufacture nanomaterials with desired properties. These developments have made it possible for focused, personalised therapies, better diagnostics and monitoring, and more effective therapy. Nanotechnology will continue to fuel growth and innovation in the nano biotechnology industry with continued research and development, opening up new opportunities and applications in numerous industries. Thus, driving the Nano Biotechnology market revenue.
Nano Biotechnology Market Segment Insights
Nano Biotechnology Application Insights
The Nano Biotechnology market segmentation, based on application includes pharmaceuticals, medical devices, medical research, food and agriculture. With 45.65% of market revenue coming from the pharmaceuticals sector, this segment led the market. Innovative approaches to medicine delivery, formulation, and development are provided by nanobiotechnology.
Figure 1: Nano Biotechnology Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Nano Biotechnology Therapeutics Insights
The Nano Biotechnology market segmentation, based on therapeutics, includes dental therapies, cardiac therapies, orthopedic therapies and others. The category with the highest revenue (51.6%) was orthopaedic therapies. Osteoarthritis, joint injuries, and fractures are all included in the diagnosis, treatment, and rehabilitation of musculoskeletal problems by orthopaedic therapy.
Nano Biotechnology Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Nano Biotechnology Market dominated this market in 2022 (45.80%). High investments in R&D initiatives, well-established research institutions for product development, government attempts to strengthen the healthcare system, and rising end-user demand are all credited with this share.Further, the U.S. Nano Biotechnology market held the largest market share, and the Canada Armor Materials market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: NANO BIOTECHNOLOGY MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Nano Biotechnology market accounts for the second-largest market share. The main drivers of the growth of the nanobiotechnology market are the high demand for technologically improved products and well-established R&D facilities.Further, the German Nano Biotechnology market held the largest market share, and the UK Nano Biotechnology market was the fastest growing market in the European region
The Asia-Pacific Nano Biotechnology Market is expected to grow at the fastest CAGR from 2023 to 2032. increasing government R&D investment for the creation of nanotechnological devices and the rapid uptake of nanotechnology in medical diagnosis. Moreover, China’s Nano Biotechnology market held the largest market share, and the Indian Nano Biotechnology market was the fastest growing market in the Asia-Pacific region.
Nano Biotechnology Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Nano Biotechnology market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Nano Biotechnology industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Nano Biotechnology industry to benefit clients and increase the market sector. In recent years, the Nano Biotechnology industry has offered some of the most significant advantages to medicine. Major players in the Nano Biotechnology market, including Ablynx (Belgium), Nami Therapeutics (US), Celgene Corporation (US), Nanophase Technologies Corporation (US), Sigma-Aldrich (US), SkyePharma Pharmaceuticals (France), Nanobiotix(France), Dabur Pharma (India), are attempting to increase market demand by investing in research and development operations.
A Sanofi subsidiary called Ablynx NV (Ablynx) is a biopharmaceutical business that specialises in creating Nanobodies, unique therapeutic proteins built from fragments of single-domain antibodies. The company has a portfolio of Nanobody-based therapy programmes in oncology, immuno-oncology, inflammation, and other important disease areas. The firm's exclusive Nanobody platform enables the quick development and mass production of innovative biological treatments with the potential to treat a variety of human ailments. Merck, Novartis, and Boehringer Ingelheim are just a few of the major pharmaceutical corporations with which the company has important research ties. The headquarters of Ablynx are in Ghent, Belgium.
An integrated biopharmaceutical firm that discovers, develops, produces, and distributes innovative gene and protein regulatory treatments for the treatment of cancer and immune-inflammatory illnesses is called Celgene Corp (Celgene), a division of Bristol-Myers Squibb Co. Its main product line consists of Abraxane (paclitaxel albumin-bound particles for injectable suspension), Revlimid (lenalidomide), Pomalyst (pomalidomide), and Thalomid (thalidomide) for the treatment of multiple myeloma, among other things. Through its own sales teams and distributors, the company offers its goods across Europe, the Americas, the Middle East, and Asia-Pacific. Summit, New Jersey in the US serves as the company's headquarters.
Key Companies in the Nano Biotechnology market include
Nano Biotechnology Industry Developments
May 2021:In order to develop and sell potential first-in-class radioenhancer nbtxr3 across tumour types and therapy combinations in China and other Asian markets, Nanobiotix (France) and LianBio (China) joined forces.
June 2018:China and other Asian markets will benefit from the development and marketing of the possible first-in-class radioenhancer nbtxr3 by Nanobiotix (France) and LianBio (China).
Nano Biotechnology Market Segmentation
Nano Biotechnology Application Outlook
-
Pharmaceuticals
-
Medical Devies
-
Medical Research
-
Food and Agriculture
Nano Biotechnology Therapeutics Outlook
-
Dental Therapies
-
Cardiac Therapies
-
Orthopedic Therapies
-
Others
Nano Biotechnology Regional Outlook
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
Report Attribute/Metric |
Details |
Market Size 2022 |
USD 5.1 Billion |
Market Size 2023 |
USD 5.58 Billion |
Market Size 2032 |
USD 11.6 Billion |
Compound Annual Growth Rate (CAGR) |
9.60% (2023-2032) |
Base Year |
2022 |
Market Forecast Period |
2023-2032 |
Historical Data |
2018- 2022 |
Market Forecast Units |
Value (USD Billion) |
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Type, Distribution Channel, and Region |
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
Countries Covered |
The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
Key Companies Profiled |
Ablynx (Belgium), Nami Therapeutics (US), Celgene Corporation (US), Nanophase Technologies Corporation (US), Sigma-Aldrich (US), SkyePharma Pharmaceuticals (France), Nanobiotix(France), Dabur Pharma (India) |
Key Market Opportunities |
Government support and funding |
Key Market Dynamics |
Advancements in nanotechnologyIncreasing demand for personalized medicine |
Nano Biotechnology Market Highlights:
Frequently Asked Questions (FAQ) :
The Nano Biotechnology market size was valued at USD 5.1 Billion in 2022.
The market is projected to grow at a CAGR of 9.60% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are General Mills Inc., Amway, Conagra Brands Inc., Cargill Incorporated, Abbott Laboratories, Kraft Foods Group Inc., The Coca-Cola Company.
The beverage category dominated the market in 2022.
The store based had the largest share in the market.